Abstract
ObjectivesARRIVAL (NCT02725567) is a single-arm, Phase 3 study of the pharmacokinetics (PK) and safety of ivacaftor (IVA) in patients aged <24 months with cystic fibrosis (CF) with ≥1 CFTR gating...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
